Evidence map›Paper›PMID 35097154›Full record

ArticleOpen forum infectious diseases2022

Trimethoprim-Sulfamethoxazole Versus Levofloxacin for

Sadia H Sarzynski, Sarah Warner, Junfeng Sun, Roland Matsouaka, John P Dekker, Ahmed Babiker, Willy Li, Yi Ling Lai, Robert L Danner, Vance G Fowler and 1 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
9.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Infection and drug resistance · 2026
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. ASM case reports · 2025
    Article
  12. Cefiderocol treatment for patients infected by Stenotrophomonas maltophilia, Burkholderia cepacia complex and Achromobacter spp.: subgroup analysis from the PERSEUS study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Observational
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Antibiotics (Basel, Switzerland) · 2024
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Sadia H SarzynskiCritical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
Sarah WarnerCritical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
Junfeng SunCritical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
Roland MatsouakaDepartment of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA.
John P DekkerBacterial Pathogenesis and Antimicrobial Resistance Unit, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.
Ahmed BabikerDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0003-0578-4871
Willy LiPharmacy Department, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
Yi Ling LaiCritical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
Robert L DannerCritical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
Vance G FowlerDepartment of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA.
Sameer S KadriCritical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0002-4420-9004
National Institutes of Health Clinical Center · USDuke University · USEmory University · USNational Institute of Allergy and Infectious Diseases · US

Funding

Application of Genomic Approaches to Bacterial Pathogenesis and Mechanisms of Antimicrobial ResistanceZIAAI001249 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DEKKER, JOHN · 2019 to 2025
$13.7M
Preclinical and Clinical Investigations of Severe Infection and Critical Illness ZIACL008060 · CLC · CLINICAL CENTER · PI DANNER, ROBERT L · 2009 to 2025
$0k
Big Data- Epidemiology of Antimicrobial ResistanceZIACL090046 · CLC · CLINICAL CENTER · PI KADRI, SAMEER · 2017 to 2025
$0k
6 · The paper itself

Abstract

backgroundTrimethoprim-sulfamethoxazole (TMP-SMX) is considered first-line therapy for

methodsAdult inpatient encounters January 2005 through December 2017 with growth of

resultsAmong 1581 patients with

conclusionsBased on observational evidence, levofloxacin is a reasonable alternative to TMP-SMX for the treatment of bloodstream and lower respiratory tract infections caused by

Indexed as

levofloxacinStenotrophomonas maltophiliaTMP-SMXtrimethoprim-sulfamethoxazole

Identifiers

PMID35097154
PMCPMC8794591
OpenAlexW4205621195

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.